Rafael Firszt, MD
Allergy/ Immunology · Salt Lake City, UTNPI 1659533669
Payments from drug & device makers
Across 670 payments — averaging $1638.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$627K
- Amgen$235K
- Regeneron$92K
- Takeda Pharmaceuticals U.S.A., Inc.$53K
- Astrazeneca UK Limited$31K
- Chiesi USA, Inc.$21K
- plus $40K from 28 others
What the payments were for
- Consulting fees$8,18543%
- Speaking & faculty fees$2,52513%
- Travel & lodging$1,82510%
- Food & beverage$6,52234%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $626,932 |
| Amgen | 45 | $234,576 |
| Regeneron | 206 | $92,019 |
| Takeda Pharmaceuticals U.S.A., Inc. | 74 | $52,631 |
| Astrazeneca UK Limited | 2 | $30,893 |
| Chiesi USA, Inc. | 10 | $20,692 |
| CSL Behring | 23 | $17,412 |
| Genentech USA, Inc. | 13 | $7,561 |
| Shire North American Group Inc | 18 | $5,387 |
| ARS Pharmaceuticals Operations, Inc. | 14 | $4,086 |
| Teva Pharmaceuticals USA, Inc. | 16 | $2,391 |
| Sanofi | 48 | $626 |
| GSK | 22 | $376 |
| Pharming Healthcare, Inc. | 14 | $375 |
| Regeneron Healthcare Solutions, Inc. | 13 | $315 |
| Novartis | 13 | $266 |
| Biocryst US Sales Co., LLC | 10 | $229 |
| Kaleo, Inc. | 12 | $220 |
| Boehringer Ingelheim | 9 | $158 |
| Grifols USA, LLC | 8 | $139 |
| Pfizer | 6 | $92 |
| Galderma Laboratories, L.p. | 3 | $66 |
| Blueprint Medicines Corporation | 3 | $59 |
| LEO Pharma Inc. | 3 | $56 |
| Organon | 3 | $52 |
| Bio Products Laboratory USA, Inc. | 3 | $46 |
| AbbVie | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Lilly USA, LLC | 2 | $43 |
| Circassia Inc. | 2 | $38 |
| Alk-abello, Inc | 2 | $36 |
| Biocryst Pharmaceuticals, Inc. | 2 | $29 |
| Optinose US, Inc. | 2 | $26 |
| Octapharma USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy/ immunology providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 26 | $94,792 |
| XolairOmalizumab | 22 | $60,517 |
| Famotidine | 40 | $786 |
| Montelukast Sodium | 28 | $263 |
| Fluticasone Propionate | 19 | $254 |
Paid to pharmacies, not to this prescriber.
Other allergy/ immunology in Salt Lake City
- Kay WalkerSalt Lake City$206
- Kenneth PinnaSaint George$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.